Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngeneā€™s platform for fully integrated therapeutic discovery and development across large and small molecules.Ā 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support theirĀ Ā R&DĀ Ā goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Quality focus

We are a fully digitized quality organization with a strong compliance track record with global regulators. Our facilities are US FDA, EMA, and PMDA approved, GLP certified, and AAALAC accredited. In the last financial year, we completed 78 client and regulator audits.

Manufacturing capacity

An API commercial manufacturing capacity of 70,000 L and a biologics commercial manufacturing capacity of 28,000 L (expandable); commercial-scale sterile fill-finish facility with a capacity of 1 million vials per day.

Sustainability

As part of our commitment to sustainability, we recycled 38% water, consumed 75% renewable energy, and recycled 90.75% waste. We also had zero environmental violations.

Green chemistry innovation

Implemented green chemistry across process design, process development, execution, and disposal phases. Also, reduced raw materials, solvents, waste, and disposal.

Flexible business models

Offering various business models such as dedicated R&D labs (for long-term partnerships), fee-for-service, full-time equivalent, and risk-reward models (milestone-based).

Robust supply chain

A network of 2500+ suppliers across 30+ countries, contracts with global partners, 24X7 local arrangements, and extended support to local partners.

Quality focus

We are a fully digitized quality organization with a strong compliance track record with global regulators. Our facilities are US FDA, EMA, and PMDA approved, GLP certified, and AAALAC accredited. In the last financial year, we completed 78 client and regulator audits.

Manufacturing capacity

An API commercial manufacturing capacity of 70,000 L and a biologics commercial manufacturing capacity of 28,000 L (expandable); commercial-scale sterile fill-finish facility with a capacity of 1 million vials per day.

Sustainability

As part of our commitment to sustainability, we recycled 38% water, consumed 75% renewable energy, and recycled 90.75% waste. We also had zero environmental violations.

Green chemistry innovation

Implemented green chemistry across process design, process development, execution, and disposal phases. Also, reduced raw materials, solvents, waste, and disposal.

Flexible business models

Offering various business models such as dedicated R&D labs (for long-term partnerships), fee-for-service, full-time equivalent, and risk-reward models (milestone-based).

Robust supply chain

A network of 2500+ suppliers across 30+ countries, contracts with global partners, 24X7 local arrangements, and extended support to local partners.

Ā 

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details